
  
    
      
        Background_NNP
        
          Free_JJ radicals_NNS and_CC DNA-damage_NNP in_IN diabetes_NN
          Free-radicals_NNP (_( 
          e_SYM ._. g_SYM ._. ,_, superoxide_NN ,_, hydroxyl_NN
          radicals_NNS ,_, nitric_JJ oxide_NN and_CC peroxynitrite_NN )_) have_VBP long_RB been_VBN
          thought_VBN to_TO be_VB a_DT key_JJ element_NN in_IN the_DT cellular_JJ dysfunction_NN
          and_CC death_NN that_WDT are_VBP central_JJ to_TO the_DT pathogenesis_NNS of_IN many_JJ
          aspects_NNS of_IN diabetes_NN ._. In_IN type_NN 1_CD diabetes_NN ,_, it_PRP has_VBZ been_VBN
          shown_VBN that_IN inflammatory_JJ cytokines_NNS play_VBP a_DT central_JJ role_NN in_IN
          the_DT destruction_NN of_IN insulin_NN producing_VBG β-cells_JJ [_NN 17_CD 18_CD 19_CD ]_NN
          ,_, resulting_VBG in_IN the_DT production_NN of_IN oxygen-derived_JJ free_JJ
          radicals_NNS that_WDT induce_VB DNA-damage_NNP and_CC apoptosis_NNS in_IN both_DT
          rodent_NN and_CC human_JJ β-cells_JJ [_NN 20_CD 21_CD 22_CD 23_CD 24_CD 25_CD ]_NN ._. In_IN both_DT
          type_NN 1_CD and_CC type_NN 1_CD ,_, as_RB well_RB as_RB ,_, type_NN 2_CD diabetes_NN ,_, the_DT role_NN
          of_IN free_JJ radicals_NNS in_IN diabetic_JJ complications_NNS is_VBZ well_RB
          studied_VBN ._. The_DT most_RBS prominent_JJ feature_NN of_IN diabetes_NN ,_,
          hyperglycemia_NN ,_, is_VBZ believed_VBN to_TO augment_VB free_JJ radical_JJ
          production_NN [_NN 26_CD ]_NN ,_, probably_RB due_JJ to_TO the_DT increased_VBN
          mitochondrial_NN oxidative_JJ metabolism_NN that_WDT is_VBZ secondary_JJ to_TO a_DT
          high_JJ intracellular_NN glucose_NN concentration_NN ._. Glucose_NNP also_RB
          leads_VBZ to_TO advanced_VBN glycation_NN end_NN products_NNS ,_, which_WDT initiate_VBP
          free_JJ radical_JJ cascades_NNS and_CC are_VBP toxic_JJ to_TO cells_NNS ,_, including_VBG
          β-cells_JJ [_NN 27_CD 28_CD ]_NN ._.
          Free_JJ radicals_NNS cause_VBP damage_NN to_TO cells_NNS by_IN various_JJ
          mechanisms_NNS ,_, resulting_VBG in_IN damage_NN to_TO proteins_NNS ,_, lipids_NNS ,_, and_CC
          nucleic_JJ acids_NNS ,_, 
          i_NNP ._. e_SYM ._. ,_, virtually_RB all_DT cellular_JJ
          structures_NNS ._. In_IN particular_JJ ,_, free_JJ radicals_NNS may_MD lead_VB to_TO
          nuclear_JJ and_CC mitochondrial_NN DNA_NNP damage_NN and_CC mutations_NNS ,_,
          causing_VBG diminished_VBN proliferative_JJ capacity_NN ,_, premature_JJ
          cellular_JJ senescence_NN ,_, and_CC impaired_VBN mitochondrial_NN function_NN
          [_NN 29_CD 30_CD ]_NN ._. For_IN the_DT β-cell_JJ ,_, one_CD of_IN the_DT most_RBS metabolically_RB
          active_JJ cells_NNS in_IN the_DT body_NN ,_, mitochondrial_NN function_NN is_VBZ
          essential_JJ ,_, and_CC diabetes_NN is_VBZ a_DT prominent_JJ feature_NN of_IN many_JJ
          primary_JJ disorders_NNS of_IN mitochondrial_NN function_NN [_NN 30_CD ]_NN ._.
          While_IN free_JJ radicals_NNS play_VBP a_DT central_JJ role_NN in_IN the_DT
          pathogenesis_NNS of_IN many_JJ aspects_NNS of_IN diabetes_NN and_CC it_PRP is_VBZ known_VBN
          that_IN free_JJ radicals_NNS can_MD cause_VB DNA_NNP damage_NN ,_, direct_JJ evidence_NN
          is_VBZ sparse_NN for_IN DNA_NNP damage_NN in_IN the_DT pathogenesis_NNS of_IN β-cell_JJ
          failure_NN in_IN type_NN 2_CD diabetes_NN ._. The_DT exceptions_NNS are_VBP a_DT study_NN in_IN
          which_WDT it_PRP was_VBD reported_VBN that_IN the_DT oxygen_NN radical_JJ derived_VBN DNA_NNP
          adduct_NN 7_CD ,_, 8_CD -_: dihydro-_NN 8_CD -_: oxoguanosine_NN (_( 8_CD -_: OH-dG_NNP )_) is_VBZ present_JJ in_IN
          the_DT islets_NNS of_IN diabetic_JJ Goto-_NNP Kakizaki_NNP rats_NNS ,_, a_DT model_NN of_IN
          type_NN 2_CD diabetes_NN [_NN 31_CD ]_NN ._. Also_RB ,_, after_IN submission_NN of_IN the_DT
          present_JJ study_NN ,_, it_PRP was_VBD reported_VBN that_IN an_DT increased_VBN number_NN
          of_IN 8_CD -_: OH-dG_NNP positive_JJ islet_NN cells_NNS is_VBZ observed_VBN in_IN pancreata_NN
          from_IN human_JJ type_NN 2_CD diabetic_JJ subjects_NNS ._. In_IN that_DT study_NN ,_, an_DT
          increased_VBN number_NN of_IN cells_NNS with_IN DNA_NNP damage_NN correlated_JJ with_IN
          a_DT decreased_VBN β-cell_JJ mass_NN [_NN 32_CD ]_NN ._.
        
        
          Hypothesis_NNP
          We_PRP hypothesized_VBN that_IN oxidative_JJ DNA_NNP damage_NN plays_VBZ a_DT role_NN
          in_IN the_DT β-cell_JJ dysfunction_NN and_CC loss_NN that_WDT occurs_VBZ in_IN human_JJ
          type_NN 2_CD diabetes_NN ._. To_TO test_VB this_DT hypothesis_NNS ,_, we_PRP screened_VBD the_DT
          gene_NN expression_NN patterns_NNS of_IN islets_NNS from_IN a_DT normal_JJ control_NN
          and_CC a_DT type_NN 2_CD diabetic_JJ subject_NN with_IN Affymetrix_NNP gene_NN chip_NN
          arrays_NNS ,_, with_IN special_JJ reference_NN to_TO genes_NNS involved_VBN in_IN DNA_NNP
          repair_NN (_( Tyrberg_NNP &_CC Levine_NNP ,_, unpublished_JJ data_NNS )_) ._. One_CD gene_NN
          that_WDT was_VBD over-expressed_JJ in_IN islets_NNS from_IN the_DT type_NN 2_CD
          diabetic_JJ subject_NN ,_, was_VBD the_DT DNA_NNP glycosylase_NN 8_CD -_: OxoG_NNP DNA_NNP
          glycosylase_NN (_( Ogg_NNP 1_LS )_) ._. This_DT enzyme_NN is_VBZ the_DT major_JJ repair_NN
          enzyme_NN involved_VBN in_IN the_DT defense_NN against_IN accumulation_NN of_IN
          the_DT 8_CD -_: OH-dG_NNP adducts_NNS discussed_VBN above_IN ._. In_IN light_NN of_IN the_DT
          previous_JJ publication_NN on_IN the_DT role_NN of_IN 8_CD -_: OH-dG_NNP adducts_NNS in_IN a_DT
          rat_NN model_NN of_IN type_NN 2_CD diabetes_NN [_NN 31_CD ]_NN ,_, and_CC the_DT finding_VBG
          that_IN the_DT Ogg_NNP 1_CD gene_NN was_VBD over-expressed_JJ in_IN human_JJ type_NN 2_CD
          diabetes_NN ,_, we_PRP evaluated_VBD the_DT expression_NN of_IN Ogg_NNP 1_CD protein_NN in_IN
          pancreas_NN specimens_NNS from_IN type_NN 2_CD diabetic_JJ and_CC healthy_JJ
          subjects_NNS ,_, as_IN a_DT marker_NN for_IN β-cell_JJ oxidative_JJ DNA_NNP damage_NN in_IN
          type_NN 2_CD diabetes_NN ._.
        
      
      
        Methods_NNP
        
          Tissue_NNP collection_NN
          Specimens_NNP from_IN human_JJ pancreata_NN were_VBD collected_VBN in_IN La_NNP
          Jolla_NNP ,_, CA_NNP ;_: Sofia_NNP ,_, Bulgaria_NNP ;_: Seoul_NNP ,_, South_NNP Korea_NNP and_CC São_NNP
          Paolo_NNP ,_, Brazil_NNP ,_, post_NN mortem_NN or_CC post_NN surgery_NN ._. Normal_NNP
          control_NN subjects_NNS were_VBD never_RB diagnosed_VBN with_IN any_DT form_NN of_IN
          diabetes_NN while_IN patients_NNS with_IN type_NN 2_CD diabetes_NN had_VBD been_VBN
          diagnosed_VBN 2_CD ,_, 7_CD ,_, 15_CD ,_, 20_CD or_CC 23_CD years_NNS before_IN the_DT specimens_NNS
          were_VBD collected_VBN ._. Diagnoses_NNP were_VBD based_VBN on_IN hospital_NN records_NNS ._.
          The_DT patient_NN with_IN a_DT 23_CD year_NN history_NN of_IN diabetes_NN also_RB had_VBD a_DT
          history_NN of_IN alcoholism_NN ._. None_NN of_IN the_DT subjects_NNS had_VBD a_DT history_NN
          of_IN receiving_VBG cancer_NN therapy_NN ,_, a_DT possible_JJ confounding_VBG
          factor_NN in_IN the_DT analysis_NN of_IN DNA_NNP damage_NN ._. More_RBR detailed_JJ
          patient_NN records_NNS are_VBP found_VBN in_IN Table_NNP 1_CD ._.
        
        
          Immunofluorescent_NNP staining_VBG and_CC fluorescence_NN
          microscopy_NN
          Sections_NNP from_IN human_JJ pancreata_NN were_VBD double_JJ stained_JJ for_IN
          Ogg_NNP 1_CD and_CC somatostatin_NN ,_, as_IN a_DT marker_NN for_IN the_DT islets_NNS ,_, with_IN
          rabbit_NN anti-human_JJ Ogg_NNP 1_CD (_( Novus_NNP Biologicals_NNP ,_, Littleton_NNP ,_, CO_NNP )_)
          and_CC goat_NN anti-human_JJ somatostatin_NN antibodies_NNS (_( Santa_NNP Cruz_NNP
          Biotechnology_NNP ,_, Santa_NNP Cruz_NNP ,_, CA_NNP )_) ,_, after_IN antigen_NN retrieval_NN
          by_IN boiling_VBG for_IN 10_CD min_NN in_IN acidic_JJ antigen_NN retrieval_NN
          solution_NN (_( Biogenex_NNP ,_, San_NNP Ramon_NNP ,_, CA_NNP )_) ._. Antibody_NNP binding_JJ was_VBD
          detected_VBN with_IN an_DT Alexa_NNP 488_CD donkey_NN anti-rabbit_JJ antibody_NN
          (_( Molecular_NNP Probes_NNP ,_, Eugene_NNP ,_, OR_NNP )_) and_CC an_DT Alexa_NNP 590_CD donkey_NN
          anti-goat_JJ antibody_NN (_( Molecular_NNP Probes_NNP )_) ._. All_DT sections_NNS were_VBD
          finally_RB counter-stained_JJ with_IN nuclear_JJ DAPI_NNP staining_VBG
          (_( Molecular_NNP Probes_NNP )_) ,_, and_CC mounted_VBD with_IN anti-fading_JJ mounting_VBG
          media_NNS (_( DAKO_NNP fluorescent_NN mounting_VBG media_NNS ,_, DAKO_NNP ,_, Glostrup_NNP ,_,
          Denmark_NNP )_) ._. To_TO evaluate_VB the_DT specificity_NN of_IN the_DT Ogg_NNP 1_CD
          antibody_NN ,_, slides_NNS were_VBD stained_JJ with_IN fluorescent_NN secondary_JJ
          antibody_NN alone_RB ,_, which_WDT resulted_VBD in_IN no_DT background_NN staining_VBG
          (_( data_NNS not_RB shown_VBN )_) ._. Also_RB ,_, as_IN a_DT positive_JJ control_NN ,_, pancreas_NN
          from_IN a_DT mouse_NN injected_VBN with_IN the_DT oxidative_JJ radical_JJ inducing_VBG
          agent_NN alloxan_NN [_NN 33_CD ]_NN ,_, were_VBD stained_JJ one_CD day_NN after_IN the_DT
          injection_NN ,_, with_IN a_DT marked_VBN increase_NN of_IN Ogg_NNP 1_CD nuclear_JJ and_CC
          cytoplasmic_JJ staining_VBG as_IN a_DT result_NN (_( data_NNS not_RB shown_VBN )_) ._.
          Tissue_NNP sections_NNS were_VBD examined_VBN in_IN a_DT fluorescent_NN
          microscope_NN with_IN 200_CD -_: 400_CD ×_NN magnification_NN ._. The_DT pancreatic_JJ
          islets_NNS were_VBD evaluated_VBN blindly_RB with_IN semi-quantitative_JJ
          morphological_JJ scoring_VBG of_IN fluorescent_NN intensity_NN :_: 0_CD ,_, no_DT or_CC
          very_RB weak_JJ Ogg_NNP 1_CD staining_VBG ;_: 1_CD ,_, moderate_JJ Ogg_NNP 1_CD staining_VBG ;_: and_CC
          2_CD ,_, strong_JJ Ogg_NNP 1_CD staining_VBG ._. They_PRP were_VBD also_RB scored_VBN for_IN Ogg_NNP 1_CD
          positive_JJ islet_NN area_NN as_IN follows_VBZ :_: 0_CD ;_: no_DT or_CC very_RB small_JJ area_NN
          of_IN the_DT islet_NN stained_JJ for_IN Ogg_NNP 1_CD ;_: 25_CD ,_, approximately_RB 25_CD %_NN of_IN
          the_DT islet_NN area_NN was_VBD Ogg_NNP 1_CD positive_JJ ;_: 50_CD ,_, approximately_RB 50_CD %_NN ;_:
          75_CD ,_, approximately_RB 75_CD %_NN ;_: and_CC 100_CD ,_, approximately_RB 100_CD %_NN ._. The_DT
          total_JJ number_NN of_IN islets_NNS evaluated_VBN in_IN the_DT five_CD pancreata_NN
          from_IN type_NN 2_CD diabetic_JJ patients_NNS were_VBD 232_CD (_( 46_CD ._. 4_LS ±_NN 8_CD ._. 5_CD per_IN
          pancreas_NN )_) and_CC in_IN the_DT seven_CD pancreata_NN from_IN normal_JJ
          controls_NNS :_: 306_CD (_( 43_CD ._. 7_CD ±_NN 8_CD ._. 6_CD per_IN pancreas_NN )_) ._. Sections_NNP were_VBD
          evaluated_VBN live_VB in_IN the_DT fluorescence_NN microscope_NN with_IN a_DT
          combined_VBN filter_NN for_IN green_JJ and_CC red_JJ fluorescence_NN ,_, which_WDT
          means_VBZ that_DT camera_NN exposure_NN time_NN and_CC other_JJ camera_NN
          settings_NNS ,_, did_VBD not_RB influence_VB the_DT intensity_NN of_IN the_DT Ogg_NNP 1_CD
          staining_VBG ._. Also_RB ,_, the_DT Alexa_NNP dyes_NNS are_VBP very_RB stable_JJ
          fluorophores_NNS ,_, even_RB under_IN UV_NNP light_JJ exposure_NN ,_, so_IN that_IN
          fading_VBG is_VBZ unlikely_JJ to_TO be_VB a_DT significant_JJ issue_NN in_IN
          influencing_VBG the_DT results_NNS [_NN 34_CD ]_NN ._.
        
        
          Ethics_NNP
          Human_JJ tissue_NN collection_NN were_VBD approved_VBN by_IN the_DT
          respective_JJ local_JJ human_JJ IRBs_NNP (_( UCSD_NNP ,_, La_NNP Jolla_NNP ,_, CA_NNP ;_: Veterans_NNP
          Hospital_NNP ,_, La_NNP Jolla_NNP ,_, CA_NNP ;_: Military_NNP Medical_NNP Academy_NNP ,_, Sofia_NNP ,_,
          Bulgaria_NNP ;_: University_NNP Hospital_NNP of_IN São_NNP Paolo_NNP ,_, São_NNP Paolo_NNP ,_,
          Brazil_NNP ;_: The_DT Catholic_NNP University_NNP of_IN Korea_NNP ,_, Seoul_NNP ,_, South_NNP
          Korea_NNP )_) ._. No_DT information_NN that_WDT would_MD identify_VB the_DT subjects_NNS
          was_VBD provided_VBN ._.
        
        
          Statistical_NNP analysis_NN
          Data_NNP are_VBP presented_VBN as_IN means_VBZ ±_NN SEM_NNP ._. The_DT average_JJ
          semi-quantitative_JJ unparametric_JJ morphological_JJ scores_NNS for_IN
          each_DT individual_NN was_VBD compared_VBN with_IN Mann-_NNP Whitney_NNP 's_POS
          unparametric_JJ test_NN ._.
        
      
      
        Results_NNS
        Pancreatic_NNP paraffin_NN sections_NNS from_IN five_CD type_NN 2_CD diabetic_JJ
        subjects_NNS and_CC seven_CD healthy_JJ controls_NNS were_VBD compared_VBN by_IN
        immunohistochemistry_NN for_IN Ogg_NNP 1_CD ._. Co-staining_NNP for_IN somatostatin_NN
        as_IN a_DT marker_NN of_IN islets_NNS of_IN Langerhans_NNP was_VBD performed_VBN (_( Fig_NNP ._. 1_LS )_) ._.
        Somatostatin_NNP rather_RB than_IN insulin_NN was_VBD chosen_VBN as_IN an_DT islet_NN
        marker_NN because_IN insulin_NN expression_NN can_MD be_VB significantly_RB
        decreased_VBN in_IN islets_NNS from_IN patients_NNS with_IN longstanding_JJ type_NN 2_CD
        diabetes_NN ._.
        Two_CD parameters_NNS were_VBD chosen_VBN to_TO measure_VB islet_NN Ogg_NNP 1_CD
        expression_NN ._. The_DT percentage_NN of_IN the_DT islet_NN that_IN stained_JJ
        positively_RB for_IN Ogg_NNP 1_CD was_VBD used_VBN as_IN a_DT measure_NN of_IN the_DT number_NN of_IN
        Ogg_NNP 1_CD -_: expressing_VBG cells_NNS ._. The_DT intensity_NN of_IN the_DT Ogg_NNP 1_CD staining_VBG
        was_VBD used_VBN as_IN a_DT measure_NN of_IN the_DT level_NN of_IN Ogg_NNP 1_CD expression_NN in_IN
        positive_JJ cells_NNS ._. By_IN semi-quantitative_JJ scoring_VBG ,_, both_DT the_DT
        intensity_NN and_CC the_DT area_NN of_IN Ogg_NNP 1_CD staining_VBG were_VBD significantly_RB
        increased_VBN (_( P_NN <_NN 0_CD ._. 05_CD and_CC P_NN <_NN 0_CD ._. 02_CD ,_, respectively_RB )_) in_IN
        islets_NNS from_IN the_DT type_NN 2_CD diabetic_JJ subjects_NNS compared_VBN to_TO the_DT
        healthy_JJ controls_NNS (_( Fig_NNP ._. 2_LS ,_, 3_CD ,_, 4_CD ,_, 5_LS )_) ._. Interestingly_RB ,_, the_DT Ogg_NNP 1_CD
        fluorescent_NN staining_VBG intensity_NN ,_, but_CC not_RB the_DT percent_NN
        positive_JJ islet_NN area_NN ,_, increases_NNS with_IN increasing_VBG duration_NN of_IN
        diabetes_NN (_( Fig_NNP ._. 6_CD )_) ._. Pancreatic_NNP exocrine_NN tissue_NN expressed_VBD
        Ogg_NNP 1_CD at_IN various_JJ degrees_NNS (_( Fig_NNP ._. 1_LS )_) ,_, but_CC no_DT correlation_NN was_VBD
        found_VBN with_IN type_NN 2_CD diabetes_NN (_( data_NNS not_RB shown_VBN )_) ._.
      
      
        Discussion_NNP
        This_DT study_NN demonstrates_VBZ that_IN the_DT enzyme_NN Ogg_NNP 1_CD ,_, which_WDT is_VBZ
        involved_VBN in_IN the_DT repair_NN of_IN oxidative_JJ DNA_NNP damage_NN ,_, is_VBZ
        up-regulated_JJ in_IN the_DT islets_NNS of_IN patients_NNS with_IN type_NN 2_CD
        diabetes_NN ._. This_DT is_VBZ consistent_JJ with_IN the_DT hypothesis_NNS that_IN
        oxidative_JJ DNA_NNP damage_NN is_VBZ an_DT important_JJ factor_NN in_IN the_DT β-cell_JJ
        failure_NN that_WDT plays_VBZ a_DT role_NN in_IN the_DT pathogenesis_NNS of_IN human_JJ type_NN
        2_CD diabetes_NN ._.
        We_PRP interpret_VBP the_DT upregulation_NN of_IN Ogg_NNP 1_CD as_IN a_DT response_NN to_TO
        an_DT increased_VBN level_NN of_IN 8_CD -_: OH-dG_NNP DNA_NNP ,_, the_DT lesion_NN that_IN it_PRP
        repairs_VBZ ._. Increases_NNS in_IN Ogg_NNP 1_CD activity_NN and_CC expression_NN have_VBP
        been_VBN found_VBN by_IN a_DT number_NN of_IN investigators_NNS [_NN 35_CD 36_CD 37_CD ]_NN ._.
        Although_IN antibodies_NNS to_TO 8_CD -_: OH-dG_NNP exist_VB [_NN 38_CD ]_NN ,_, Ogg_NNP 1_CD was_VBD used_VBN
        as_IN a_DT surrogate_NN for_IN the_DT amount_NN of_IN oxidative_JJ DNA_NNP damage_NN ._. The_DT
        reason_NN for_IN this_DT is_VBZ that_IN we_PRP found_VBD high_JJ levels_NNS of_IN background_NN
        staining_VBG with_IN the_DT anti-_NN 8_CD -_: OH-dG_NNP antibodies_NNS ,_, which_WDT is_VBZ not_RB
        unusual_JJ when_WRB using_VBG streptavidin_NN /_NN biotin_NN detection_NN systems_NNS in_IN
        immunohistochemistry_NN [_NN 39_CD ]_NN ._. Unfortunately_RB ,_, secondary_JJ
        antibodies_NNS directly_RB linked_VBN to_TO a_DT fluorophore_NN or_CC a_DT detection_NN
        enzyme_NN were_VBD not_RB sensitive_JJ enough_RB to_TO detect_VB the_DT 8_CD -_: OH-dG_NNP
        adduct_NN in_IN our_PRP$ hands_NNS ._.
        The_DT mechanism_NN by_IN which_WDT Ogg_NNP 1_CD protein_NN is_VBZ increased_VBN in_IN type_NN
        2_CD diabetic_JJ islets_NNS is_VBZ unknown_JJ ._. The_DT promoter_NN of_IN the_DT Ogg_NNP 1_CD gene_NN
        does_VBZ not_RB have_VB a_DT TATA_NNP box_NN [_NN 40_CD ]_NN ,_, but_CC Ogg_NNP 1_CD is_VBZ
        differentially_RB expressed_VBN in_IN the_DT rat_NN CNS_NNP ,_, and_CC its_PRP$ expression_NN
        is_VBZ increased_VBN after_IN mouse_NN forebrain_NN ischemia-reperfusion_JJ [_NN
        35_CD 36_CD ]_NN ,_, suggesting_VBG that_DT regulation_NN occurs_VBZ ,_, either_CC at_IN the_DT
        transcriptional_NN or_CC post-transcriptional_JJ level_NN ._.
        Unfortunately_RB ,_, there_EX have_VBP been_VBN no_DT studies_NNS of_IN the_DT effects_NNS of_IN
        long-term_JJ chronic_JJ increases_NNS in_IN oxidative_JJ DNA_NNP damage_NN on_IN Ogg_NNP 1_CD
        expression_NN ._. The_DT association_NN between_IN the_DT duration_NN of_IN
        diabetes_NN and_CC Ogg_NNP 1_CD levels_NNS (_( Fig_NNP ._. 6_CD )_) suggests_VBZ that_IN such_JJ
        long-term_JJ exposure_NN may_MD be_VB important_JJ for_IN Ogg_NNP 1_CD
        up-regulation_JJ ._.
        Most_JJS of_IN the_DT staining_VBG observed_VBN was_VBD detected_VBN in_IN the_DT
        cytoplasm_NN of_IN the_DT islet_NN cells_NNS ._. As_IN Ogg_NNP 1_CD either_CC is_VBZ
        sublocalized_JJ into_IN the_DT nucleus_NN or_CC the_DT mitochondria_NN ,_, this_DT
        indicates_VBZ that_DT βOgg_NN 1_CD ,_, the_DT mitochondrial_NN form_NN of_IN Ogg_NNP 1_CD ,_,
        accounts_NNS for_IN the_DT observed_VBN increase_NN ._. βOgg_NN 1_CD is_VBZ an_DT
        alternatively_RB spliced_JJ form_NN of_IN Ogg_NNP 1_CD that_WDT contains_VBZ a_DT
        mitochondrial_NN targeting_VBG signal_NN in_IN the_DT C-_NNP terminal_NN portion_NN of_IN
        the_DT protein_NN [_NN 41_CD ]_NN ._. Specific_JJ upregulation_NN of_IN mitochondrial_NN
        but_CC not_RB nuclear_JJ Ogg_NNP 1_CD occurs_VBZ during_IN aging_VBG in_IN rodents_NNS [_NN 42_CD ]_NN
        ._. A_DT specific_JJ increase_NN of_IN Ogg_NNP 1_CD in_IN islet_NN cell_NN mitochondria_NN is_VBZ
        consistent_JJ with_IN the_DT idea_NN that_WDT increased_VBD β-cell_JJ
        mitochondrial_NN oxidative_JJ metabolism_NN due_JJ to_TO hyperglycemia_NN is_VBZ
        a_DT major_JJ factor_NN behind_IN the_DT DNA_NNP damage_NN ._. In_IN a_DT study_NN published_VBN
        after_IN this_DT report_NN was_VBD submitted_VBN ,_, an_DT increased_VBN number_NN of_IN
        8_CD -_: OH-dG_NNP positive_JJ islet_NN cells_NNS in_IN human_JJ type_NN 2_CD diabetic_JJ
        subjects_NNS was_VBD observed_VBN [_NN 32_CD ]_NN ._. The_DT staining_VBG was_VBD found_VBN to_TO be_VB
        mainly_RB nuclear_JJ in_IN contrast_NN to_TO the_DT cytoplasmic_JJ Ogg_NNP 1_CD staining_VBG
        found_VBN in_IN the_DT present_JJ report_NN ._. Unfortunately_RB ,_, we_PRP were_VBD unable_JJ
        to_TO obtain_VB specific_JJ staining_VBG with_IN antibodies_NNS to_TO 8_CD -_: OH-dG_NNP ._.
        However_RB ,_, the_DT nuclear_JJ localization_NN of_IN 8_CD -_: OH-dG_NNP [_NN 32_CD ]_NN and_CC the_DT
        increased_VBN Ogg_NNP 1_CD reported_VBD here_RB are_VBP consistent_JJ with_IN a_DT model_NN in_IN
        which_WDT mitochondrial_NN Ogg_NNP 1_CD is_VBZ up-regulated_JJ but_CC nuclear_JJ Ogg_NNP 1_CD
        is_VBZ not_RB ,_, leading_VBG to_TO an_DT increase_NN in_IN nuclear_JJ but_CC not_RB
        mitochondrial_NN 8_CD -_: OH-dG_NNP adducts_NNS [_NN 32_CD ]_NN ._. Further_RB studies_VBZ will_MD
        be_VB required_VBN to_TO resolve_VB this_DT issue_NN ,_, but_CC β-cells_JJ in_IN type_NN 2_CD
        diabetes_NN may_MD well_RB suffer_VB from_IN both_DT nuclear_JJ and_CC
        mitochondrial_NN DNA_NNP damage_NN ,_, leading_VBG to_TO decreased_VBD β-cell_JJ
        function_NN and_CC eventual_JJ loss_NN of_IN β-cell_JJ mass_NN ._.
        In_IN this_DT study_NN ,_, both_DT the_DT area_NN and_CC the_DT intensity_NN of_IN Ogg_NNP 1_CD
        staining_VBG were_VBD assessed_VBN ._. Since_IN it_PRP was_VBD not_RB practical_JJ to_TO
        collect_VB specimens_NNS in_IN a_DT controlled_VBN manner_NN ,_, it_PRP could_MD be_VB
        argued_VBN that_IN differences_NNS in_IN fixation_NN technique_NN could_MD affect_VB
        the_DT fluorescence_NN intensity_NN of_IN the_DT immunostaining_VBG ._. However_RB ,_,
        as_IN we_PRP also_RB detected_VBD a_DT significant_JJ increase_NN in_IN the_DT islet_NN
        area_NN stained_JJ for_IN Ogg_NNP 1_CD ,_, we_PRP are_VBP confident_JJ that_DT islet_NN cell_NN
        Ogg_NNP 1_CD is_VBZ actually_RB upregulated_JJ in_IN type_NN 2_CD diabetes_NN ._. The_DT direct_JJ
        correlation_NN between_IN the_DT fluorescence_NN intensity_NN and_CC the_DT
        duration_NN of_IN diabetes_NN that_WDT held_VBD true_JJ for_IN samples_NNS collected_VBN
        from_IN disparate_JJ locations_NNS also_RB argues_VBZ in_IN favor_NN of_IN the_DT
        hypothesis_NNS ._. It_PRP is_VBZ interesting_JJ that_IN the_DT Ogg_NNP 1_CD positive_JJ area_NN
        did_VBD not_RB show_VB the_DT same_JJ increase_NN with_IN increasing_VBG duration_NN of_IN
        diabetes_NN as_IN the_DT Ogg_NNP 1_CD staining_VBG intensity_NN ._. We_PRP have_VBP observed_VBN
        that_IN the_DT number_NN of_IN β-cells_JJ varies_VBZ considerably_RB in_IN the_DT
        islets_NNS from_IN type_NN 2_CD diabetic_JJ subjects_NNS and_CC that_IN large_JJ areas_NNS
        of_IN the_DT islets_NNS are_VBP sometimes_RB replaced_VBN by_IN amorphous_JJ material_NN
        (_( data_NNS not_RB shown_VBN )_) ,_, probably_RB reflecting_VBG fibrosis_NNS or_CC
        amyloidosis_NNS ._. Such_JJ a_DT variation_NN in_IN cell_NN number_NN per_IN islet_NN
        would_MD bias_NN a_DT correlation_NN of_IN Ogg_NNP 1_CD positive_JJ cells_NNS with_IN
        duration_NN of_IN diabetes_NN ._. Moreover_RB ,_, it_PRP is_VBZ possible_JJ that_IN β-cells_JJ
        from_IN patients_NNS with_IN longstanding_JJ diabetes_NN have_VBP a_DT higher_JJR
        threshold_NN for_IN an_DT apoptotic_JJ response_NN to_TO DNA-damage_NNP than_IN
        β-cells_JJ in_IN normal_JJ subjects_NNS ,_, as_IN it_PRP has_VBZ been_VBN shown_VBN that_IN this_DT
        threshold_NN increases_NNS with_IN age_NN [_NN 43_CD ]_NN ._. Consequently_RB ,_, β-cells_JJ
        with_IN high_JJ levels_NNS of_IN DNA_NNP damage_NN from_IN younger_JJR individuals_NNS
        with_IN a_DT shorter_JJR duration_NN of_IN diabetes_NN might_MD be_VB eliminated_VBN by_IN
        apoptosis_NNS ,_, while_IN similarly_RB damaged_VBN β-cells_JJ from_IN older_JJR
        individuals_NNS ,_, who_WP are_VBP likely_JJ to_TO have_VB had_VBN diabetes_NN for_IN a_DT
        longer_JJR time_NN may_MD be_VB resistant_JJ to_TO apoptosis_NNS and_CC so_RB remain_VB ._.
        Such_JJ an_DT apoptotic_JJ defect_NN could_MD account_VB for_IN the_DT increasing_VBG
        intensity_NN of_IN Ogg_NNP 1_CD staining_VBG ,_, following_VBG accumulated_VBN levels_NNS of_IN
        8_CD -_: OH-dG_NNP adducts_NNS with_IN longer_JJR duration_NN of_IN diabetes_NN ._. Further_RB
        epidemiological_JJ studies_NNS in_IN which_WDT age_NN was_VBD specifically_RB
        studied_VBN would_MD be_VB required_VBN to_TO address_VB this_DT issue_NN more_RBR
        definitively_RB ._.
        We_PRP noted_VBD that_IN the_DT variability_NN in_IN the_DT amount_NN of_IN Ogg_NNP 1_CD
        staining_VBG is_VBZ higher_JJR in_IN the_DT control_NN group_NN than_IN in_IN the_DT samples_NNS
        from_IN the_DT diabetic_JJ patients_NNS ._. It_PRP is_VBZ well_RB known_VBN that_IN there_EX is_VBZ
        a_DT high_JJ incidence_NN of_IN undiagnosed_JJ diabetes_NN in_IN the_DT general_JJ
        population_NN ._. Since_IN detailed_JJ patient_NN records_NNS were_VBD not_RB
        available_JJ ,_, it_PRP is_VBZ possible_JJ that_IN undiagnosed_JJ diabetes_NN in_IN the_DT
        control_NN group_NN could_MD account_VB for_IN the_DT increased_VBN
        variability_NN ._.
        Ogg_NNP 1_CD knockout_NN mice_NNS possess_VBP increased_VBN levels_NNS of_IN 8_CD -_: OH-dG_NNP
        in_IN their_PRP$ genome_NN ,_, particularly_RB in_IN the_DT mitochondrial_NN genome_NN ,_,
        but_CC do_VBP not_RB seem_VB to_TO exhibit_VB an_DT increased_VBN frequency_NN of_IN
        malignancies_NNS [_NN 44_CD 45_CD 46_CD ]_NN ._. It_PRP was_VBD postulated_JJ that_IN the_DT
        consequences_NNS of_IN 8_CD -_: OH-dG_NNP adducts_NNS and_CC Ogg_NNP 1_CD deficiency_NN affects_VBZ
        mainly_RB cells_NNS with_IN high_JJ oxygen_NN metabolism_NN and_CC slow_JJ
        proliferation_NN ,_, such_JJ as_IN liver_NN cells_NNS [_NN 45_CD ]_NN ._. While_IN β-cells_JJ
        were_VBD not_RB examined_VBN in_IN that_DT study_NN ,_, they_PRP certainly_RB exhibit_NN
        both_DT high_JJ oxidative_JJ metabolism_NN and_CC a_DT low_JJ rate_NN of_IN
        proliferation_NN ,_, consistent_JJ with_IN them_PRP being_VBG a_DT target_NN for_IN the_DT
        effects_NNS of_IN 8_CD -_: OH-dG_NNP adducts_NNS ._. It_PRP would_MD be_VB of_IN great_JJ interest_NN
        to_TO study_VB the_DT Ogg_NNP 1_CD mutant_JJ mice_NNS to_TO determine_VB whether_IN an_DT
        increase_NN level_NN of_IN 8_CD -_: OH-dG_NNP adducts_NNS predisposes_NNS to_TO diabetes_NN ._.
        This_DT would_MD be_VB important_JJ in_IN establishing_VBG oxidative_JJ DNA_NNP
        damage_NN as_IN a_DT causal_NN mechanism_NN in_IN diabetes_NN as_IN opposed_VBN to_TO
        merely_RB being_VBG an_DT epiphenomenon_NN in_IN which_WDT the_DT important_JJ
        targets_NNS for_IN diabetes_NN pathogenesis_NNS lie_VBP elsewhere_RB in_IN the_DT
        β-cell_JJ ._. Further_RB epidemiological_JJ studies_NNS of_IN Ogg_NNP 1_CD expression_NN
        as_RB well_RB as_IN studies_NNS of_IN the_DT expression_NN of_IN other_JJ genes_NNS and_CC
        proteins_NNS that_WDT are_VBP involved_VBN in_IN DNA_NNP damage_NN responses_NNS should_MD
        also_RB be_VB performed_VBN to_TO further_VB test_NN the_DT hypothesis_NNS that_IN DNA_NNP
        damage_NN is_VBZ involved_VBN in_IN the_DT pathogenesis_NNS of_IN type_NN 2_CD
        diabetes_NN ._.
      
      
        Conclusions_NNP
        We_PRP conclude_VBP that_IN the_DT expression_NN of_IN the_DT DNA_NNP repair_NN enzyme_NN
        Ogg_NNP 1_CD is_VBZ up-regulated_JJ in_IN islets_NNS from_IN type_NN 2_CD diabetic_JJ
        specimens_NNS ._. Moreover_RB ,_, Ogg_NNP 1_CD expression_NN intensity_NN is_VBZ directly_RB
        correlated_JJ with_IN the_DT duration_NN of_IN diabetes_NN ._. These_DT finding_VBG are_VBP
        consistent_JJ with_IN the_DT hypothesis_NNS that_IN oxidative_JJ DNA_NNP damage_NN is_VBZ
        playing_VBG a_DT role_NN in_IN the_DT pathogenesis_NNS of_IN β-cell_JJ damage_NN in_IN type_NN
        2_CD diabetes_NN ._.
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' Contribution_NNP
        B_NNP ._. T_NN ._. participated_VBD in_IN the_DT design_NN of_IN the_DT study_NN ,_, carried_VBD
        out_RP the_DT immunofluorescence_NN stainings_NNS ,_, interpreted_VBD the_DT data_NNS
        and_CC wrote_VBD the_DT manuscript_NN ._. K_NNP ._. A_DT ._. A_DT ,_, S_NNP ._. A_DT ._. D_NNP ._. ,_, J_NNP ._. W-R_NNP and_CC K-H_NNP ._. Y_NNP ._.
        supplied_VBD the_DT pancreatic_JJ specimens_NNS and_CC took_VBD part_NN in_IN the_DT
        editing_NN of_IN the_DT manuscript_NN ._. F_NN ._. L_NNP ._. conceived_VBD of_IN the_DT study_NN and_CC
        participated_VBD in_IN the_DT interpretation_NN of_IN the_DT data_NNS and_CC the_DT
        writing_NN of_IN the_DT manuscript_NN ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
